Blocking both IL-1 and IL-6 alleviates severe CRS by reducing the iNOS + macrophage fraction equivalently, suggesting that NO is one unifying downstream effector of IL-1 and IL-6. The gene discussed is NOS2; the disease is congenital rubella syndrome.